Adma Biologics (ADMA) Return on Capital Employed (2011 - 2026)
Adma Biologics' (ADMA) quarterly Return on Capital Employed came in at 36.33% in Q4 2025, up 15.0% YoY from 31.59% in Q4 2024, and up 10.3% on a QoQ basis from 32.94% in Q3 2025.
Adma Biologics (ADMA) Return on Capital Employed (2011 - 2026) Analysis & Trends
Adma Biologics (ADMA) has 13 years of Return on Capital Employed data on file, last reported at 36.33% in Q4 2025.
- Quarterly Return on Capital Employed rose 15.0% year-over-year to 36.33% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 36.33% (up 15.0% YoY) and the FY2025 annual result came in at 39.32%, down 1.0% from the prior year.
- Return on Capital Employed climbed to 36.33% in Q4 2025, from 32.94% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 36.33% in Q4 2025 to a low of 31.58% in Q1 2021.
- A 5-year average of 2.67% and a median of 2.56% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed soared 3349 bps — and 2025, when it plunged 99 bps.
- Tracing ADMA's Return on Capital Employed over 5 years: stood at 25.71% in 2021, then jumped by 46 bps to 13.8% in 2022, then soared by 154 bps to 7.48% in 2023, then soared by 384 bps to 36.18% in 2024, then advanced by 0 bps to 36.33% in 2025.
- The last three Return on Capital Employed figures came in at 36.33% (Q4 2025), 32.94% (Q3 2025), and 33.87% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn | 36.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 36.13% |
| Dec 31, 2025 | 36.33% |
| Sep 30, 2025 | 32.94% |
| Jun 30, 2025 | 33.87% |
| Mar 31, 2025 | 34.08% |
| Dec 31, 2024 | 36.18% |
| Sep 30, 2024 | 33.93% |
| Jun 30, 2024 | 26.28% |
| Mar 31, 2024 | 15.43% |
| Dec 31, 2023 | 7.48% |
| Sep 30, 2023 | 0.44% |
| Jun 30, 2023 | -5.55% |
| Mar 31, 2023 | -8.24% |
| Dec 31, 2022 | -13.80% |
| Sep 30, 2022 | -18.28% |
| Jun 30, 2022 | -18.81% |
| Mar 31, 2022 | -22.27% |
| Dec 31, 2021 | -25.71% |
| Sep 30, 2021 | -30.68% |
| Jun 30, 2021 | -28.59% |